$XTALPI(02228.HK)On September 5th, at the 2025 Hong Kong Exchange Future Tech Summit, Ma Jian, co-founder and CEO of Jingtai Technology, stated during a panel discussion that the pharmaceutical industry is one of the most promising fields for AI applications. Taking molecular discovery in drug development as an example, he explained that the main process of drug development includes molecular design, synthesis, testing, and feedback, with the synthesis phase accounting for over 50% of the time. By introducing AI and robotics, Jingtai Technology has significantly reduced repetitive manual labor in experiments, improving automation in this phase. Additionally, it has achieved standardized and complete data collection, which serves as 'fuel' for the iterative optimization of AI models, further reducing the number of experiments, enhancing R&D efficiency, and helping pharmaceutical companies reduce costs and increase efficiency.